Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.

What Was Tested

This randomized controlled trial looks at Angiotensin-Converting Enzyme Inhibitors.

The researchers investigated whether the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist offers better control of proteinuria and cardiovascular parameters without causing adverse side effects.

Who Took Part

According to the abstract, 10 children were involved.

The age groups tagged for this paper are children and teenagers, both men and women.

The researchers enrolled 10 children (mean age: 12.3 +/- 4.06 years) with proteinuria resulting from chronic renal diseases of various causes.

During phase 1 (3 months), each child was assigned randomly to treatment with either an angiotensin-converting enzyme inhibitor or an angiotensin II type 1 receptor antagonist alone.

How the Study Was Run

The design is described as randomized.

Because people in this Angiotensin-Converting Enzyme Inhibitors study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The study consisted of 2 phases, 3 months each, for an overall 6-month observation time.

During phase 2, each child was advanced to combination therapy with the addition of an angiotensin II type 1 receptor antagonist or an angiotensin-converting enzyme inhibitor, respectively.

Renal function tests, echocardiography, and 24-hour ambulatory blood pressure monitoring were performed at the beginning of the study (time 0), at 3 months (time 1), and at 6 months (time 2).

What Was Measured

PubMed files the paper under topics including Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Hypertrophy, Left Ventricular, Kidney Diseases and Proteinuria.

What This Means in Plain Language

The paper is a randomized study of Angiotensin-Converting Enzyme Inhibitors in 10 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Pediatrics), a journal based in United States.

More context: all human trials.